关键词：乳腺癌；个案报道；文献综述；SCI期刊
所以本期就特请美国恒祥咨询的小伙伴，通过大数据分析，找出最近5年发表个案报告（case report(s)）或病例系列(case series)+文献综述的乳腺癌研究领域期刊。分析机构：Healsan Consulting LLC（美国恒祥咨询公司）检索词：((("breast cancer"[Title] OR "TNBC"[Title]) AND "case*"[Title]) NOT "control"[Title]) AND 2018/01/01:3000/12/31[Date - Publication] AND "literature review"[Title]个案报告或者病例系列是医生之间交流和相互学习的重要途径。设计的主题包括：罕见病例、提示不同发病机制的特殊病例、罕见症状、特殊的治疗方法、药物罕见不良反应、罕见解剖结构、罕见家族等等。
个案报告/病例系列经常是临床新发现的基础。但在循证医学的背景下，却因位于临床证据的底层而被忽视。不过，个案报告加上文献复习就会使研究更加丰满，证据变得更充分，部分杂志可以论著发表；而病例系列如果加上分组和统计分析，则会升级为病例-对照研究。Medline数据库已经收录了从2018年起该领域发表的99篇相关论文。分析显示，中国发表的该领域论文最多，其次是美国、日本、意大利和澳大利亚。
发表消化科个案报告/病例系列的SCI期刊中，发文最多的依次是Front Oncol、Medicine (Baltimore)、Onco Targets Ther、BMC Cancer、Curr Oncol等期刊。特别需要注意的是，期刊标记为IF=0意味着该期刊没有被SCI收录。
这些期刊的影响因子、分区以及从投稿到接受的天数如下。我们也勾出了相对来说接受速度比较快的期刊。
（期刊的影响因子、分区以及从投稿到接受的天数）
1: Chen ML, Yu W, Cui B, Yu Y, Ma Z. HER2-positive metastatic breast cancer withbrain metastases responds favorably to pyrotinib and trastuzumab-basedtreatment: A case report and literature review. Front Oncol. 2023 Jan19;12:980635. doi: 10.3389/fonc.2022.980635. PMID: 36741701; PMCID: PMC9893407.2: Mao Y, Lv M, Wang Y, Cao W, Li W. Hormone receptor-positive, HER2-negative,metastatic breast cancer responded well to abemaciclib and exemestane afterpalbociclib and fulvestrant failure: A case report and literature review. FrontOncol. 2023 Jan 9;12:1022913. doi: 10.3389/fonc.2022.1022913. PMID: 36698413;3: Jin X, Yan M, Li F. Durable effect of pyrotinib plus capecitabine in HER-2+breast cancer patient undergoing peritoneal dialysis: A case report andliterature review. Front Oncol. 2022 Dec 8;12:1059670. doi:10.3389/fonc.2022.1059670. PMID: 36568221; PMCID: PMC9780055.4: Chu Z. Abemaciclib plus fulvestrant for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer withcystic brain metastases: A case report and literature review. Front Oncol. 2022Nov 30;12:984454. doi: 10.3389/fonc.2022.984454. PMID: 36531067; PMCID:5: Li Y, Zhang L, Yu H, Xin X, He J, Yao Y, Liu B, Li R, Xie L. Case Report:Small intestinal metastatic breast cancer: A case report and literature review.Front Oncol. 2022 Nov 23;12:900832. doi: 10.3389/fonc.2022.900832. PMID:36505863; PMCID: PMC9732937.6: Drohan A, Vidovic D, Barnes PJ, Giacomantonio CA, Helyer LK. Cutaneous BreastCancer Metastasis Is Effectively Treated With Intralesional Interleukin-2 andImiquimod: A Case Report and Brief Literature Review. Front Oncol. 2022 May30;12:877014. doi: 10.3389/fonc.2022.877014. PMID: 35712509; PMCID: PMC9192334.7: Chi Y, Shang M, Xu L, Gong H, Tao R, Song L, Zhang B, Yin S, Cong B, Li H.Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive BreastCancer With Leptomeningeal Disease: A Case Report and Literature Review. FrontOncol. 2022 Feb 16;12:811919. doi: 10.3389/fonc.2022.811919. PMID: 35251981;8: Ruan B, Niu Z, Jiang X, Li Z, Tai Y, Huang H, Sun Q. High Frequency of Cell-in-Cell Formation in Heterogeneous Human Breast Cancer Tissue in a Patient WithPoor Prognosis: A Case Report and Literature Review. Front Oncol. 2019 Dec19;9:1444. doi: 10.3389/fonc.2019.01444. PMID: 31921689; PMCID: PMC6930920.1: Li D, Liu X, Cui S, Yang D, Zhu Y, Pan E, Yang P, Dai Z. A Primary Lung and
Breast Cancer Patient with Germline <i>EGFR</i> R776H Mutation: A Case Report
and Literature Review. Onco Targets Ther. 2023 Jan 18;16:17-22. doi:
10.2147/OTT.S391766. PMID: 36698436; PMCID: PMC9868143.
2: Qu Y, Liu Y, Ding K, Li Y, Hong X, Zhang H. Partial Response to Pyrotinib
Plus Capecitabine in an Advanced Breast Cancer Patient with <i>HER2</i>
Amplification and <i>R157W</i> Mutation After Anti-<i>HER2</i> Treatment: A Case
Report and Literature Review. Onco Targets Ther. 2021 Mar 2;14:1581-1588. doi:
10.2147/OTT.S289876. PMID: 33688205; PMCID: PMC7936716.
3: Martuszewski A, Paluszkiewicz P, Nowak M, Szewczyk K, Staszek-Szewczyk U.
Triple Discordances in Receptor Status During Breast Cancer Local Progression
and Metastases: Case Report and Literature Review. Onco Targets Ther. 2020 Oct
13;13:10343-10349. doi: 10.2147/OTT.S260848. Erratum in: Onco Targets Ther. 2021
Feb 04;14:807. PMID: 33116614; PMCID: PMC7569034.
4: Zhong GB, Ye XQ, Liu JL, Xiao SZ, Huang QH, Wei W. Male accessory breast
cancer on the abdominal wall: a case report and literature review. Onco Targets
Ther. 2018 Oct 8;11:6625-6631. doi: 10.2147/OTT.S184185. PMID: 30349296; PMCID:
PMC6188187.
Breast Cancer (Dove Med Press)发表的论文Wu J, Jin Y, Liu M, Zhu N, Jing Z, Zeng X. Recurrent Metaplastic Breast Cancer with Subtype Converted from Triple-Negative to HER2-Positive: A Case Report and Literature Review. Breast Cancer (Dove Med Press). 2023 Jan 19;15:39-45. doi: 10.2147/BCTT.S395944. PMID: 36698553; PMCID: PMC9869906.
备注：在投稿前请再次核对读者指南，以再次确认是否仍然收录个案报告。
编辑：Henry，微信号：Healsan。
报告机构：
Healsan Consulting，特长于医学生物大数据分析、临床数据库利用及医学统计分析；成为越来越多生物制药公司、科研机构和医生科学家“外挂医学部”。
分析软件及致谢：
文献鸟app。扫描下面二维码并用email注册，可以获得你所关注的最新研究论文摘要的每天免费推送；如需进一步了解文献鸟VIP服务，可与我们联系。
（扫码👆，注册文献鸟）
